Fewer than
0
%
EFPIA Patients W.A.I.T. Indicator 2024 Survey Published May 2025
of all EMA approved orphan medicines are available in all 27 EU member states
By applying intelligent new approaches to market access, we identify opportunities to broaden patient access to medicines.
Our Approach
How We Create Access
01
60 days
Identify Access Gaps
Health analytics led with modelling completed within 60 days
02
120 days
Act Quickly
Defined action plan with commercial partner agreements often within 120 days
03
120 days
Partner to Deliver Impact
Robust supply chain integrated into local healthcare system and launch readiness within 120 days
Beyond Medicines
Value for Health Systems & Payors
Our approach delivers value beyond medicines for patients, healthcare professionals and healthcare systems.
- Supporting patients to get the most from their medicines
- Supporting clinician-patient conversations
- Championing sustainable access to rare disease medicines